Abstract
Fungal infections represent a life-threatening complication for patients receiving chemotherapy or undergoing hematopoietic stem cell transplantation. Historically, antifungal monotherapy is associated with a poor outcome. We treated three children with hematological malignancies and proven fungal infections (one cerebral mold infection, one disseminated Candida infection, one naso-pharyngeal mucor infection) with combination antifungal therapy plus granulocyte-colony-stimulation-factor-mobilized granulocyte transfusions as secondary prophylaxis during subsequent neutropenic episodes. With this approach, the fungal infection was effectively treated, and the anticancer therapy was completed without major delay. All children survived the fungal infection and the underlying malignancy. These experiences illustrate the feasibility of this approach using more than one antifungal agent together with immune-therapy in high-risk patients.
References
Antachopoulos C, Walsh TJ (2005) New agents for invasive mycoses in children. Curr Opin Pediatr 17:78–87
Erdem I, Kucukercan M, Ceran N (2004) In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. Chemotherapy 49:294–297
Flynn TN, Kelsey SM, Hazel DL, Guest JF (1999) Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK. Pharmacoeconomics 16:543–550
Grigull L, Schrauder A, Schmitt-Thomssen A, Sykora K, Welte K (2002) Efficacy and safety of G-CSF mobilized granulocyte transfusions in four neutropenic children with sepsis and invasive fungal infection. Infection 30:267–271
Jantunen E, Ruutu P, Piilonen A, Volin L, Parkkali T, Ruutu T (2000) Treatment and outcome of invasive Aspergillus infections in allogeneic BMT recipients. Bone Marrow Transplant 26:759–762
Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW (2004) Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48:4574–4581
Kerr JP, Liakopolou E, Brown J, Cornish JM, Fleming D, Massey E, Oakhill A, Pamphilon DH, Robinson SP, Totem A, Valencia AM, Marks DI (2003) The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. Br J Haematol 123:114–118
Klastersky J (2004) Antifungal therapy in patients with fever and neutropenia—more rational and less empirical? N Engl J Med 351:1445–1447
Kontoyiannis DP, Lewis RE (2003) Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resist Updat 6:257–269
Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA (2005) Combination treatment of invasive fungal infections. Clin Microbiol Rev 18:163–194
Roilides E, Lyman CA, Panagopoulou P, Chanock S (2003) Immunomodulation of invasive fungal infections. Infect Dis Clin North Am 17:193–219
Torres HA, Kontoyiannis DP, Rolston KV (2004) High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study. Support Care Cancer 12(7):511–516
Wiederhold NP, Lewis RE, Kontoyiannis DP (2003) Invasive aspergillosis in patients with hematologic malignancies. Pharmacotherapy 23:1592–1610
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grigull, L., Beilken, A., Schmid, H. et al. Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies. Support Care Cancer 14, 783–786 (2006). https://doi.org/10.1007/s00520-005-0910-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-005-0910-8